Breaking News
Investing Pro 0
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data

Pfizer raises 2019 forecast as sales of cancer drug, heart medicine surge

Stock Markets Oct 29, 2019 10:55AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. A logo for Pfizer is displayed on a monitor on the floor at the NYSE in New York
 
GSK
+0.85%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
PFE
-0.63%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
VTRS
-0.08%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Tamara Mathias and Aakash B

(Reuters) - Pfizer Inc (N:PFE) posted third-quarter profit well above analysts' estimates on higher sales of cancer drug Ibrance and new heart medicine Vyndaqel, encouraging the largest U.S. drugmaker to lift its earnings forecast for the year.

Shares of the company rose 3.4% on Tuesday as the results suggested that Chief Executive Officer Albert Bourla's efforts to slim down the sprawling drugmaker were paying off.

Pfizer announced in July it would separate its off-patent branded drugs business and combine it with generic drugmaker Mylan NV (O:MYL), allowing it to focus on its more profitable drugs.

Bourla said on Tuesday Pfizer would become a "smaller, science-based company" following the Mylan deal, which is expected to close next year.

Pfizer raised its 2019 adjusted earnings per share forecast to between $2.94 and $3.00 from a prior estimate of between $2.76 and $2.86. Analysts on average were expecting $2.82 per share, according to Refinitiv IBES.

Although sales of Ibrance rose to $1.28 billion and those of rheumatoid arthritis drug Xeljanz jumped nearly 39% to $599 million, analysts called out Vyndaqel as the biggest surprise in the quarter.

Vyndaqel, chemically known as tafamidis, was approved in May and brought in revenue of $156 million, nearly double the consensus estimate of $82 million.

Priced at $225,000 per year, Vyndaqel's high cost has faced criticism, with experts affiliated with Boston-based Institute for Clinical and Economic Review (ICER) warning that it could be among the most costly cardiovascular treatments ever sold.

"Importantly, Ibrance is back to strong growth after a period of slowing ... (and) the Vyndaqel number in particular is impressive," UBS analyst Navin Jacob said.

The company also said sales of its patented medicines benefited from demand in emerging markets, which contribute about a quarter of total sales.

Net income attributable to Pfizer's shareholders rose nearly 87% to $7.68 billion, or $1.36 per share, as the company recognized a gain of $8.1 billion after closing its consumer health joint venture with Britain's GlaxoSmithKline Plc (L:GSK).

Excluding special items, Pfizer earned 75 cents per share, easily beating the average estimate of 62 cents.

Investor sentiment on Pfizer has been poor since it announced the deal with Mylan, making the third-quarter beat a relief, Jacob said.

Including Tuesday's gains, Pfizer shares had lost about 11% of their value since the deal with Mylan was announced.

Total revenue fell about 5% to $12.68 billion as sales of pain treatment Lyrica, which recently lost patent protection in the United States, more than halved to $527 million.

Pfizer raises 2019 forecast as sales of cancer drug, heart medicine surge
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email